COLLEGIUM PHARMACEUTICAL INC

Collegium Pharmaceutical Inc. specializes in the manufacturing of pharmaceutical preparations, with demonstrated expertise in the development and production of specialized drug formulations, including hematological and therapeutic agents. The company operates within the regulated pharmaceutical manufacturing environment, adhering to cGMP standards to ensure product quality, consistency, and safety for clinical use. Their technical capabilities encompass formulation science, active pharmaceutical ingredient processing, sterile and non-sterile manufacturing, and supply chain compliance critical to federal healthcare procurement. The firm’s focus on complex drug products suggests specialization in niche therapeutics requiring precise dosage control and regulatory rigor, positioning them as a reliable source for mission-critical pharmaceuticals. The company has delivered pharmaceutical products to the Department of Veterans Affairs under a Federal Supply Schedule contract, indicating a direct relationship with VA’s pharmacy and clinical supply networks. This engagement reflects proven ability to meet VA’s stringent requirements for drug availability, batch traceability, and distribution logistics for veteran care programs. The nature of the award suggests alignment with VA’s focus on chronic condition management and hematological therapeutics. Collegium’s primary industry focus is NAICS 325412—pharmaceutical preparation manufacturing—where they produce finished dosage forms for clinical use, distinguishing themselves in the federal market through specialized drug production rather than bulk API supply. Their market positioning centers on serving government healthcare systems requiring high-assurance, regulated pharmaceuticals with validated manufacturing processes. As a 2L entity based in Stoughton, Massachusetts, Collegium Pharmaceutical Inc. operates as a mid-sized manufacturer with no public certifications on record. Their geographic presence supports federal procurement through direct manufacturing and distribution capabilities, serving as a domestic source for critical pharmaceuticals within the federal supply chain.